Screener
Viking Therapeutics VKTX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 115,893,943 shares issued and outstanding at March 31, 2026 and 114,793,067 shares issued and outstanding at December 31, 2025 | 1 | 1 |
| Additional paid-in capital | 1,508,643 | 1,486,229 |
| Accumulated deficit | (1,005,871) | (847,546) |
| Accumulated other comprehensive loss | (856) | 378 |
| Total stockholders’ equity | 501,917 | 639,062 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's common stock?
- Viking Therapeutics (VKTX) reported common stock of $1K in Q1 2026.
- How has Viking Therapeutics's common stock changed year-over-year?
- Viking Therapeutics's common stock decreased by 0.0% year-over-year, from $1K to $1K.
- What is the long-term trend for Viking Therapeutics's common stock?
- Over 5 years (2020 to 2025), Viking Therapeutics's common stock has grown at a 0.0% compound annual growth rate (CAGR), from $1K to $1K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Viking Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude